| Aug 1 |
C4 Therapeutics GAAP EPS of -$0.26, revenue of $12M
|
| Aug 1 |
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 1 |
C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
|
| Jul 17 |
C4 Therapeutics (CCCC) Soars 13.7%: Is Further Upside Left in the Stock?
|
| Jul 16 |
C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024
|
| Jul 9 |
C4 Therapeutics (CCCC) Upgraded to Buy: Here's Why
|
| Jul 8 |
C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day
|
| Jun 30 |
C4 Therapeutics, Inc. (CCCC): Is This the Best Biotech Penny Stock to Buy Now?
|
| Jun 14 |
It Looks Like C4 Therapeutics, Inc.'s (NASDAQ:CCCC) CEO May Expect Their Salary To Be Put Under The Microscope
|
| Jun 13 |
C4 Therapeutics: Losing Steam And Presenting An Opportunity
|
